Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia-Reference-Cited by-同舟云学术

Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia

Published:2024-02-14 Issue:14 Volume:20 Page:903-918
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncol.

Author:

Goebell Peter J¹^ORCID,Raina Rutika²^ORCID,Chen Stephanie³^ORCID,Rege Sanika²⁴^ORCID,Shah Ruchit²⁵^ORCID,Grossman Jamie Partridge³^ORCID,Waldeck A Reginald³^ORCID

Affiliation:

1. Division of Urology, University Hospital Erlangen, 91054, Erlangen, Germany

2. OPEN Health, Bethesda, MD20814, USA

3. Bayer Healthcare Pharmaceuticals, Inc., Whippany, NJ07981, USA

4. Present address: Center for Pharmacoepidemiology & Treatment Science, Rutgers University, New Brunswick, NJ08901, USA

5. Present address: Daiichi Sankyo, Inc., Basking Ridge, NJ07920, USA

Funder

Bayer Healthcare Pharmaceuticals, Inc.

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.2217/fon-2023-0814

Reference67 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Epidemiology of Prostate Cancer

3. Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer.

4. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial

5. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-life Data on First- and Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer With Abiraterone, Enzalutamide and Cabazitaxel – A multicentric Study From Portugal;Clinical Genitourinary Cancer;2024-12

2. Impact of time to metastatic disease onset and extent of disease volume across metastatic hormone-sensitive and castration-resistant prostate cancer;Urologic Oncology: Seminars and Original Investigations;2024-11

3. Real‐world prevalence of adverse events with first‐line systemic therapies among patients with metastatic castration‐sensitive prostate cancer;The Prostate;2024-08-20

4. Aktueller Behandlungsstandard und Trends der Systemtherapie beim metastasierten hormonsensiblen Prostatakarzinom – Anwendung der Studiendaten in der Praxis;Die Urologie;2024-08-14